Verrica Pharmaceuticals Inc (NASDAQ:VRCA) Receives Average Recommendation of “Buy” from Analysts

Shares of Verrica Pharmaceuticals Inc (NASDAQ:VRCA) have earned a consensus rating of “Buy” from the six analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $21.67.

VRCA has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $24.00 price objective on shares of Verrica Pharmaceuticals in a research note on Monday, May 18th. Needham & Company LLC reaffirmed a “buy” rating and set a $20.00 price objective on shares of Verrica Pharmaceuticals in a research note on Thursday, April 16th. ValuEngine raised shares of Verrica Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, March 17th. Zacks Investment Research downgraded shares of Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday. Finally, BidaskClub raised shares of Verrica Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, June 23rd.

Several hedge funds and other institutional investors have recently made changes to their positions in VRCA. Citigroup Inc. increased its stake in shares of Verrica Pharmaceuticals by 41.4% during the first quarter. Citigroup Inc. now owns 3,656 shares of the company’s stock valued at $40,000 after purchasing an additional 1,071 shares in the last quarter. BNP Paribas Arbitrage SA increased its stake in shares of Verrica Pharmaceuticals by 54.2% during the first quarter. BNP Paribas Arbitrage SA now owns 4,017 shares of the company’s stock valued at $44,000 after purchasing an additional 1,412 shares in the last quarter. Meeder Asset Management Inc. bought a new position in shares of Verrica Pharmaceuticals during the fourth quarter valued at approximately $69,000. Alliancebernstein L.P. increased its stake in shares of Verrica Pharmaceuticals by 32.7% during the first quarter. Alliancebernstein L.P. now owns 13,400 shares of the company’s stock valued at $146,000 after purchasing an additional 3,300 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Verrica Pharmaceuticals during the first quarter valued at approximately $167,000. 34.45% of the stock is owned by institutional investors and hedge funds.

NASDAQ VRCA traded up $0.03 during trading on Wednesday, hitting $14.22. 1,658 shares of the company’s stock traded hands, compared to its average volume of 71,313. The stock has a fifty day moving average of $11.80 and a two-hundred day moving average of $12.72. The company has a debt-to-equity ratio of 0.61, a current ratio of 27.45 and a quick ratio of 27.45. Verrica Pharmaceuticals has a 12-month low of $6.79 and a 12-month high of $18.67. The firm has a market cap of $375.02 million, a P/E ratio of -11.91 and a beta of 2.39.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.01). As a group, analysts expect that Verrica Pharmaceuticals will post -2.32 earnings per share for the current fiscal year.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.

Featured Story: Purposes and Functions of the Federal Reserve

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.